Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer.

"CONFLICT OF INTEREST STATEMENT Yasuhiro Kodera reports personal fees from Ono Pharmaceutical Co., Ltd. and Daiichi Sankyo Co., Ltd. and research funds from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Yakult Honsha Co., Ltd. Yuichi Ando reports personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Bayer Holding Ltd., research funds from Beigene, and grants from Geo Holdings related to efforts other than the submitted work. The other authors have no conflicts of interest to declare."

"The study adhered to the guidelines outlined in the Clinical Trials Act (the Ministry of Health, Labor, and Welfare, Japan) and the Declaration of Helsinki. Approval for the trial was obtained from the Institutional Review Board of Nagoya University Hospital (approval no. 2019‐0518). Before participating in the study, all the subjects provided written informed consent. The trial details were registered with the Japan Registry of Clinical Trials (jRCTs041190129). Registry and the registration number of the study: This trial was registered with the Japan Registry of Clinical Trials (jRCTs041190129)."